Considering the patient's medication profile, which of the following best explains how the combination of fluticasone propionate/salmeterol and warfarin might interact, potentially affecting the patient's treatment plan?
Fluticasone/salmeterol decreases the effectiveness of warfarin by inducing CYP3A4, reducing anticoagulation. Fluticasone/salmeterol and warfarin have no known interactions due to different metabolic pathways. Fluticasone/salmeterol may enhance the anticoagulant effect of warfarin by inhibiting CYP3A4, leading to an increased risk of bleeding. Fluticasone/salmeterol increases the metabolism of warfarin through SLCO1B1, leading to decreased anticoagulation.